Journal
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
Volume 16, Issue -, Pages 110-118Publisher
ELSEVIER
DOI: 10.1016/j.pdpdt.2016.10.001
Keywords
Photodynamic therapy; Cholangiocarcinoma; Efficacy; Safety; Intraductal ultrasonography; Systemic inflammatory response
Categories
Funding
- Health Department of Zhejiang Provence [2013KYB204, 2016RCB015]
- Health Department of Hangzhou [2014Z01]
- Zhejiang medical technology project [2013KYB204, 2016RCB015]
- Hangzhou medical technology project [2014Z01]
Ask authors/readers for more resources
Background: The available evidence of Photodynamic therapy (PDT) combined with stent placement treatment for unresectable extrahepatic cholangiocarcinoma (EHCC) is still insufficient. It also remains unclear whether PDT influences systemic inflammatory response. Aim: To explore the clinical efficacy and safety of the combination treatment and the systemic inflammatory response in patients with EHCC. Methods: Patients with unresectable EHCC underwent either the combined treatment using Hematoporphyrin PDT and stent placement (PDT + stent group, n = 12) or stent-only (stent group, n = 27). The primary end-point was overall survival. Tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 levels were measured. Quality of life was assessed using the Karnofsky performance scale (KPS) every 3 months. Results: Average survival time (13.8 vs. 9.6 months), and 6-month (91.7% vs. 74.1%), and 1-year (58.3% vs. 3.7%) survival rates of PDT + stent group were significantly increased compared with the stent group. KPS scores in the PDT + stent group were significantly improved. TNF-alpha and IL-6 levels were significantly increased in the PDT + stent group. Conclusion: Hematoporphyrin-PDT combined with stent placement is an effective and safe treatment for EHCC. The treatment might promote systemic inflammatory response. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available